As filed with the Securities and Exchange Commission on March 29, 2023

Registration No. 333-            

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

AN2 Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   82-0606654

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

1800 El Camino Real, Suite D

Menlo Park, California 94027

(650) 331-9090

(Address of principal executive offices, including zip code)

AN2 Therapeutics, Inc. 2022 Equity Incentive Plan

AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan

(Full titles of the plans)

Eric Easom

Chief Executive Officer

AN2 Therapeutics, Inc.

1800 El Camino Real, Suite D

Menlo Park, California 94027

(650) 331-9090

(Name, address and telephone number, including area code, of agent for service)

 

 

Copies to:

 

Josh Seidenfeld

Sally Kay

Anitha Anne

Cooley LLP

3175 Hanover Street

Palo Alto, CA 94304

(650) 843-5000

  

Lucy O. Day

Chief Financial Officer

AN2 Therapeutics, Inc.

1800 El Camino Real, Suite D

Menlo Park, California 94027

(650) 331-9090

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ☐    Accelerated filer   ☐
Non-accelerated filer   ☒    Smaller reporting company   ☒
     Emerging growth company   ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 

EXPLANATORY NOTE

REGISTRATION OF ADDITIONAL SHARES

Pursuant to General Instruction E of Form S-8, AN2 Therapeutics, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) for the purpose of registering (i) 776,106 additional shares of its Common Stock under the 2022 Equity Incentive Plan (the “2022 Plan”), pursuant to the provisions of the 2022 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2022 Plan on January 1, 2023, and (ii) 194,026 additional shares of its Common Stock under the 2022 Employee Stock Purchase Plan (the “2022 ESPP,” together with the 2022 Plan, the “Plans”), pursuant to the provisions of the 2022 ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2022 ESPP on January 1, 2023. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

The Registrant previously registered shares of its Common Stock for issuance under the Plans on a Registration Statement on Form S-8 filed with the Commission on March 29, 2022 (File No. 333-263917). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above except as set forth below.

PART II

INFORMATION REQUIRED IN REGISTRATION STATEMENT

ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

(a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on March 29, 2023 (the “2022 Form 10-K”).

(b) The description of the Registrant’s Common Stock which is contained in the Registrant’s Registration Statement on Form 8-A filed on March 22, 2022 (File No. 001-41331) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as updated by Exhibit 4.3 to the 2022 Form 10-K, including any amendment or report filed for the purpose of updating such description.

(c) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

ITEM 4. DESCRIPTION OF SECURITIES

Not applicable.

ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL

Not applicable.

ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS

Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act of 1933, as amended (the “Securities Act”). The Registrant’s amended and restated certificate of incorporation permits indemnification of the Registrant’s directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and the Registrant’s amended and restated bylaws provide that the Registrant will indemnify its directors and executive officers and permit the Registrant to indemnify its other officers, employees and other agents, in each case to the maximum extent permitted by the Delaware General Corporation Law.

The Registrant has entered into indemnification agreements with its directors and officers, whereby it has agreed to indemnify its directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of the Registrant, provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of the Registrant. At present, there is no pending litigation or proceeding involving a director or officer of the Registrant regarding which indemnification is sought, nor is the Registrant aware of any threatened litigation that may result in claims for indemnification.

The Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his or her capacity as such.

ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.

Not applicable.

ITEM 8. EXHIBITS

 

          Incorporated by Reference  

Exhibit
Number

   

Description

    Schedule
Form		      File
Number		      Exhibit      Filing Date  
  4.1    Amended and Restated Certificate of Incorporation of the Registrant      S-1        333-263295        3.2        March 4, 2022  
  4.2    Amended and Restated Bylaws of the Registrant      S-1        333-263295        3.4        March 4, 2022  
  4.3    Form of Common Stock Certificate of the Registrant      S-1        333-263295        4.1        March 21, 2022  
  5.1*    Opinion of Cooley LLP            
23.1*    Consent of Cooley LLP (included in Exhibit 5.1)            
23.2*    Consent of Independent Registered Public Accounting Firm            

          Incorporated by Reference  
Exhibit
Number		   

Description

    Schedule
Form		      File
Number		      Exhibit      Filing Date  
  24.1*    Power of Attorney (included on the signature page of this registration statement)            
  99.1    AN2 Therapeutics, Inc. 2022 Equity Incentive Plan      S-1        333-263295        10.3        March 4, 2022  
  99.2    Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the AN2 Therapeutics, Inc. 2022 Equity Incentive Plan      S-1        333-263295        10.4        March 4, 2022  
  99.3    Form of Restricted Stock Unit Grant Notice and Award Agreement under the AN2 Therapeutics, Inc. 2022 Equity Incentive Plan      S-1        333-263295        10.5        March 4, 2022  
  99.4    AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan      S-1        333-263295        10.6        March 4, 2022  
107*    Filing Fee Table            

 

*

Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Menlo Park, State of California, on March 29, 2023.

 

AN2 THERAPEUTICS, INC.
By:   /s/ Eric Easom
  Eric Easom
  Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Eric Easom, Lucy Day and Michael A. Nazak, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

   

Title

  

Date

/s/ Eric Easom

Eric Easom

   

Chief Executive Officer and Director

(Principal Executive Officer)

   March 29, 2023

/s/ Lucy Day

Lucy Day

   

Chief Financial Officer

(Principal Financial Officer)

   March 29, 2023

/s/ Michael Nazak

Michael Nazak

   

Vice President and Controller

(Principal Accounting Officer)

   March 29, 2023

/s/ Joseph S. Zakrzewski

Joseph S. Zakrzewski

    Board Chair   March 29, 2023

/s/ Kabeer Aziz

Kabeer Aziz

    Director   March 29, 2023

/s/ Rob Readnour

Rob Readnour

    Director   March 29, 2023

/s/ Gilbert L. Marks

Gilbert L. Marks

    Director   March 29, 2023

/s/ Stephanie Wong

Stephanie Wong

    Director   March 29, 2023

/s/ Patricia Martin

Patricia Martin

    Director   March 29, 2023

/s/ Melvin Spigelman

Melvin Spigelman

    Director   March 29, 2023

/s/ Maggie FitzPatrick

Maggie FitzPatrick

    Director   March 29, 2023
Grafico Azioni AN2 Therapeutics (NASDAQ:ANTX)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di AN2 Therapeutics
Grafico Azioni AN2 Therapeutics (NASDAQ:ANTX)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di AN2 Therapeutics